BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder

S. Mattioli, E. Seregni, L. Caperna, C. Botti, G. Savelli, E. Bombardieri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This study evaluated the diagnostic accuracy of BTA-TRAK in combination with urinary cytology (UC) in the follow-up of patients with a history of transitional cell carcinoma (TCC) of the bladder. The overall sensitivity of BTA-TRAK, UC and the two tests combined for the detection of recurrences was 82.7% (48/58), 84.2% (48/57) and 91.2% (52/57), respectively. BTA and UC showed comparable sensitivity for superficial recurrences (76.7% (33/43) and 78.5% (33/42), respectively) and for invasive recurrences (100% (15/15)); when the two tests were used in combination, the sensitivity for superficial lesions increased to 88% (37/42). BTA-TRAK was more sensitive than UC for G1 recurrences (81.2% (13/16) vs. 68.7% (11/16)), and when the two tests were combined the sensitivity increased to 87.5% (14/16). The sensitivity of the combination was 100% (15/15) for G3 lesions. The differences in urinary BTA-TRAK levels between patients with recurrences and those without evidence of disease were statistically significant (Wilcoxon's test, p

Original languageEnglish
Pages (from-to)219-225
Number of pages7
JournalInternational Journal of Biological Markers
Volume15
Issue number3
Publication statusPublished - 2000

Fingerprint

Cytology
Transitional Cell Carcinoma
Cell Biology
Urinary Bladder
Cells
Recurrence

Keywords

  • Bladder tumor antigen
  • BTA
  • Transitional cell carcinoma
  • Tumor marker

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder. / Mattioli, S.; Seregni, E.; Caperna, L.; Botti, C.; Savelli, G.; Bombardieri, E.

In: International Journal of Biological Markers, Vol. 15, No. 3, 2000, p. 219-225.

Research output: Contribution to journalArticle

@article{bd6d0918da9e4cceb7f64cfb7dc470b8,
title = "BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder",
abstract = "This study evaluated the diagnostic accuracy of BTA-TRAK in combination with urinary cytology (UC) in the follow-up of patients with a history of transitional cell carcinoma (TCC) of the bladder. The overall sensitivity of BTA-TRAK, UC and the two tests combined for the detection of recurrences was 82.7{\%} (48/58), 84.2{\%} (48/57) and 91.2{\%} (52/57), respectively. BTA and UC showed comparable sensitivity for superficial recurrences (76.7{\%} (33/43) and 78.5{\%} (33/42), respectively) and for invasive recurrences (100{\%} (15/15)); when the two tests were used in combination, the sensitivity for superficial lesions increased to 88{\%} (37/42). BTA-TRAK was more sensitive than UC for G1 recurrences (81.2{\%} (13/16) vs. 68.7{\%} (11/16)), and when the two tests were combined the sensitivity increased to 87.5{\%} (14/16). The sensitivity of the combination was 100{\%} (15/15) for G3 lesions. The differences in urinary BTA-TRAK levels between patients with recurrences and those without evidence of disease were statistically significant (Wilcoxon's test, p",
keywords = "Bladder tumor antigen, BTA, Transitional cell carcinoma, Tumor marker",
author = "S. Mattioli and E. Seregni and L. Caperna and C. Botti and G. Savelli and E. Bombardieri",
year = "2000",
language = "English",
volume = "15",
pages = "219--225",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "3",

}

TY - JOUR

T1 - BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder

AU - Mattioli, S.

AU - Seregni, E.

AU - Caperna, L.

AU - Botti, C.

AU - Savelli, G.

AU - Bombardieri, E.

PY - 2000

Y1 - 2000

N2 - This study evaluated the diagnostic accuracy of BTA-TRAK in combination with urinary cytology (UC) in the follow-up of patients with a history of transitional cell carcinoma (TCC) of the bladder. The overall sensitivity of BTA-TRAK, UC and the two tests combined for the detection of recurrences was 82.7% (48/58), 84.2% (48/57) and 91.2% (52/57), respectively. BTA and UC showed comparable sensitivity for superficial recurrences (76.7% (33/43) and 78.5% (33/42), respectively) and for invasive recurrences (100% (15/15)); when the two tests were used in combination, the sensitivity for superficial lesions increased to 88% (37/42). BTA-TRAK was more sensitive than UC for G1 recurrences (81.2% (13/16) vs. 68.7% (11/16)), and when the two tests were combined the sensitivity increased to 87.5% (14/16). The sensitivity of the combination was 100% (15/15) for G3 lesions. The differences in urinary BTA-TRAK levels between patients with recurrences and those without evidence of disease were statistically significant (Wilcoxon's test, p

AB - This study evaluated the diagnostic accuracy of BTA-TRAK in combination with urinary cytology (UC) in the follow-up of patients with a history of transitional cell carcinoma (TCC) of the bladder. The overall sensitivity of BTA-TRAK, UC and the two tests combined for the detection of recurrences was 82.7% (48/58), 84.2% (48/57) and 91.2% (52/57), respectively. BTA and UC showed comparable sensitivity for superficial recurrences (76.7% (33/43) and 78.5% (33/42), respectively) and for invasive recurrences (100% (15/15)); when the two tests were used in combination, the sensitivity for superficial lesions increased to 88% (37/42). BTA-TRAK was more sensitive than UC for G1 recurrences (81.2% (13/16) vs. 68.7% (11/16)), and when the two tests were combined the sensitivity increased to 87.5% (14/16). The sensitivity of the combination was 100% (15/15) for G3 lesions. The differences in urinary BTA-TRAK levels between patients with recurrences and those without evidence of disease were statistically significant (Wilcoxon's test, p

KW - Bladder tumor antigen

KW - BTA

KW - Transitional cell carcinoma

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0033832558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033832558&partnerID=8YFLogxK

M3 - Article

C2 - 11012097

AN - SCOPUS:0033832558

VL - 15

SP - 219

EP - 225

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -